October 23, 2016 5:48 AM ET


Company Overview of Fumapharm AG

Company Overview

As of May 31, 2006, Fumapharm AG was acquired by Biogen Idec, Inc. Fumapharm AG, a pharmaceutical company, develops therapeutics. Its products include FUMADERM for the treatment of psoriasis; and BG-12 for the treatment of multiple sclerosis and psoriasis. The company was founded in 1983 and is headquartered in Luzern, Switzerland.

Tribschenstrasse 7

Luzern,  6002


Founded in 1983


41 41 371 20 46


41 41 371 20 48

Key Executives for Fumapharm AG

Fumapharm AG does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Acino International AG Europe
Albea Pharmaceuticals AG Europe
Alpen Pharma AG Europe
Alpex Pharma SA Europe
Amring Pharmaceuticals SA Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Fumapharm AG, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.